^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + decitabine (DNMT inhibitor) |
| Drug Class: | FLT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Published date:
11/05/2020
Excerpt:
...DEC10-VEN + FLT3i is safe and effective for previously treated FLT3mut AML, and an excellent frontline option for older pts with treatment-naïve AML.
DOI:
10.1182/blood-2020-137822
